BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Biotech catalysts in 2024-10

216 industry Phase 2/3 trial readout(s) and 38 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.

← 2024-09 | 2024-11 →

FDA decision events

DateEventStatusCompanyDrugSource
2024-10-03FDA approvalapprovedBRISTOL MYERS SQUIBB BMYOPDIVOApproved 2024-10-03: OPDIVO (BLA125554 SUPPL127)
2024-10-04FDA approvalapprovedBIOFRONTERA BFRIAMELUZApproved 2024-10-04: AMELUZ (NDA208081 SUPPL28)
2024-10-04FDA approvalapprovedAMNEAL AMRXPYRIDOSTIGMINE BROMIDEApproved 2024-10-04: PYRIDOSTIGMINE BROMIDE (NDA217604 ORIG1)
2024-10-07FDA AdComheldAdCom 2024-10-07: Science Board to the Food and Drug Administration Advisory Committee
2024-10-07Complete response letterapproved sinceCSL Behring LLCCSL312 (garadacimab)CRL 2024-10-07: CSL Behring LLC BLA 761367 (CSL312 (garadacimab))
2024-10-08Complete response lettercomplete responseZealand Pharma US, Inc.timely resolutionCRL 2024-10-08: Zealand Pharma US, Inc. NDA 217724/Original 1, NDA 217724 (timely resolution)
2024-10-10FDA AdComheldAdCom 2024-10-10: Vaccines and Related Biological Products Advisory Committee
2024-10-10FDA AdComheldStealth BioTherapeutics Inc.AdCom 2024-10-10: Cardiovascular and Renal Drugs Advisory Committee - NDA 215244
2024-10-10Complete response lettercomplete responseConjupro Biotherapeutics, Inc.(irinotecan liposome injection), oe )CRL 2024-10-10: Conjupro Biotherapeutics, Inc. NDA 218923 ((irinotecan liposome injection), oe ))
2024-10-10FDA approvalapprovedACCORD BIOPHARMA INC.IMULDOSAApproved 2024-10-10: IMULDOSA (BLA761364 ORIG1)
2024-10-10FDA approvalapprovedGENENTECH INCITOVEBIApproved 2024-10-10: ITOVEBI (NDA219249 ORIG1)
2024-10-11FDA approvalapprovedUCB INCBIMZELXApproved 2024-10-11: BIMZELX (BLA761151 SUPPL9)
2024-10-11FDA approvalapprovedASTRAZENECA AB AZNKOMBIGLYZE XRApproved 2024-10-11: KOMBIGLYZE XR (NDA200678 SUPPL28)
2024-10-11FDA approvalapprovedPFIZER INC PFEHYMPAVZIApproved 2024-10-11: HYMPAVZI (BLA761369 ORIG1)
2024-10-11FDA approvalapprovedASTRAZENECA AB AZNONGLYZAApproved 2024-10-11: ONGLYZA (NDA022350 SUPPL26)
2024-10-11FDA approvalapprovedEMD SERONO INCBAVENCIOApproved 2024-10-11: BAVENCIO (BLA761049 SUPPL19)
2024-10-15FDA approvalapprovedPFIZER PFEFRAGMINApproved 2024-10-15: FRAGMIN (NDA020287 SUPPL80)
2024-10-16FDA approvalapprovedALKERMES INC ALKSLUMRYZApproved 2024-10-16: LUMRYZ (NDA214755 SUPPL6)
2024-10-16FDA approvalapprovedABBVIE ABBVVYALEVApproved 2024-10-16: VYALEV (NDA216962 ORIG1)
2024-10-18FDA approvalapprovedELI LILLY AND CO LLYZEPBOUND ZEPBOUND KWIKPENApproved 2024-10-18: ZEPBOUND; ZEPBOUND (AUTOINJECTOR); ZEPBOUND KWIKPEN (NDA217806 SUPPL6)
2024-10-18FDA approvalapprovedSUMITOMO PHARMA AMORGOVYXApproved 2024-10-18: ORGOVYX (NDA214621 SUPPL6)
2024-10-18FDA approvalapprovedASTELLASVYLOYApproved 2024-10-18: VYLOY (BLA761365 ORIG1)
2024-10-18FDA approvalapprovedALLERGANBOTOX; BOTOX COSMETICApproved 2024-10-18: BOTOX; BOTOX COSMETIC (BLA103000 SUPPL5331)
2024-10-21Complete response lettercomplete responseHikma Pharmaceuticals USA Inc.CRL 2024-10-21: Hikma Pharmaceuticals USA Inc. NDA 219045
2024-10-21Complete response lettercomplete responseBridge Regulatory Affairs, LLCoctreotide hydrochloride extended- releaseCRL 2024-10-21: Bridge Regulatory Affairs, LLC NDA 218600 (octreotide hydrochloride extended- release injection)
2024-10-23FDA approvalapprovedZHUHAIBEIZRAYApproved 2024-10-23: BEIZRAY (NDA218711 ORIG1)
2024-10-23FDA approvalapprovedSHORLAJYLAMVOApproved 2024-10-23: JYLAMVO (NDA212479 SUPPL2)
2024-10-23FDA approvalapprovedSHORLAJYLAMVOApproved 2024-10-23: JYLAMVO (NDA212479 SUPPL3)
2024-10-25Complete response lettercomplete responseSun Pharmaceutical Industries Limited(nilotinib) capsulesCRL 2024-10-25: Sun Pharmaceutical Industries Limited NDA 215644 ((nilotinib) capsules)
2024-10-25FDA approvalapprovedITERUM THERAPORLYNVAHApproved 2024-10-25: ORLYNVAH (NDA213972 ORIG1)
2024-10-25FDA approvalapprovedSANOFI AVENTIS US SNYSARCLISAApproved 2024-10-25: SARCLISA (BLA761113 SUPPL11)
2024-10-25FDA approvalapprovedSANOFI AVENTIS US SNYSARCLISAApproved 2024-10-25: SARCLISA (BLA761113 SUPPL12)
2024-10-29FDA AdComheldAdCom 2024-10-29: Pharmacy Compounding Advisory Committee
2024-10-29Complete response lettercomplete responseAccord BioPharma Inc.INTPSCRL 2024-10-29: Accord BioPharma Inc. BLA 761147 (INTPS)
2024-10-29FDA approvalapprovedNOVARTIS NVSSCEMBLIXApproved 2024-10-29: SCEMBLIX (NDA215358 SUPPL8)
2024-10-29FDA approvalapprovedNOVARTIS NVSSCEMBLIXApproved 2024-10-29: SCEMBLIX (NDA215358 SUPPL9)
2024-10-30FDA AdComheldAdCom 2024-10-30: Patient Engagement Advisory Committee
2024-10-31FDA AdComheldLexicon Pharmaceuticals, Inc. LXRXAdCom 2024-10-31: Endocrinologic and Metabolic Drugs Advisory Committee

Trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2024-10 est.P3Advenchen Laboratories, LLCNCT02584478 Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, PrimaEndometrial Carcinoma; Ovarian Carcinoma; Fallopian Tube Carcinoma; Primary Peritoneal Carcinoma; Ceunknown294
2024-10 est.P2Techfields IncNCT02785120 A Study to Evaluate the Efficacy and Safety of TF0023 Spray on Subjects With Ischemic StrokesIschemic Strokesuspended225
2024-10 est.P3Philogen S.p.A.NCT02938299 Neoadjuvant L19IL2/L19TNF- Pivotal StudyMalignant Melanomaactive not recruiting214
2024-10 est.P1/P2Orca Therapeutics B.V.NCT04097002 First in Man Clinical Study to Evaluate Safety and Tolerability of an Oncolytic Adenovirus in Prostate Cancer Patients.Adenocarcinoma of the Prostateunknown24
2024-10 est.P1/P2NexImmune Inc.NCT04284228 Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCTAcute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS)unknown22
2024-10 est.P2Tracon Pharmaceuticals Inc.NCT04480502 ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or MyxofibrosarcomaUndifferentiated Pleomorphic Sarcoma; Myxofibrosarcomaunknown207
2024-10 est.P2ImmunoVaccine Technologies, Inc. (IMV Inc.)NCT04920617 DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell LymphomaRelapsed Diffuse Large B-cell Lymphoma; Refractory Diffuse Large B-cell Lymphomarecruiting102
2024-10 est.P2RemeGen Co., Ltd.NCT04965519 A Study of RC48-ADC for the Treatment of HER2-expressing Gynecological MalignanciesGynecological Malignancyunknown120
2024-10 est.P3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05145218 A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant OvariaRecurrent Platinum-resistant Ovarian Cancerunknown405
2024-10 est.P1/P2Cyclacel Pharmaceuticals, Inc.NCT05168904 A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)Leukemia; Myelodysplastic Syndrome(MDS)suspended210
2024-10 est.P2Wohlstand PharmaceuticalNCT05465798 Beta-glucans for Hospitalised Patients With COVID-19COVID-19unknown60
2024-10 est.P3Matinas BioPharma Nanotechnologies, Inc. MTNBNCT05541107 Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3Cryptococcal Meningitisunknown270
2024-10 est.P2EmbolineNCT05684146 Protect the Head to Head StudyEmbolismunknown540
2024-10 est.P3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05718167 TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced SquamoAdvanced Squamous Non-Small Cell Lung Carcinomaunknown570
2024-10 est.P1/P2Qilu Pharmaceutical Co., Ltd.NCT06041035 A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid TumorsSolid Tumorunknown115
2024-10 est.P1/P2Beijing Tide Pharmaceutical Co., LtdNCT06213363 A Phase Ib/II Clinical Study in Patients With Refractory Chronic CoughRefractory Chronic Coughunknown72
2024-10 est.P1/P2Supergenics Life Science Sdn. Bhd.NCT06231771 Safety and Efficacy of Stem Cells for Diabetic Foot UlcerDiabetic Foot Ulcerunknown22
2024-10 est.P2Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFMNCT06270225 A Study of SSGJ-613 in Gout Subjects Initiating Urate-Lowering Treatment.Gout Arthritisunknown157
2024-10-01P2/P3ImmunityBio, Inc. IBRXNCT03022825 QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive HBladder Canceractive not recruiting190
2024-10-01P3CelgeneNCT03440372 Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's DiseaseCrohn Diseaseterminated625
2024-10-01P3Healios K.K.NCT03545607 MultiStem® Administration for Stroke Treatment and Enhanced Recovery StudyIschemic Stroketerminated206
2024-10-01P3AbbVie ABBVNCT04223193 Flexible-Dose Trial in Early Parkinson's Disease (PD)Parkinson Diseasecompleted304
2024-10-01P2/P3Healios K.K.NCT04367077 MultiStem Administration for COVID-19 Induced ARDS (MACoVIA)ARDSterminated22
2024-10-01 est.P2UBP Greater China (Shanghai) Co., LtdNCT04714060 UB-621, a New Type of Anti-herpes Simplex Virus (HSV) Monoclonal Antibody for the Use in the Treatment of Adult Recurrent HSV-2 Infections of the GenitalsRecurrent Genital Herpesunknown44
2024-10-01P2Gilead Sciences GILDNCT04827576 Study of Magrolimab in Patients With Solid TumorsSolid Tumorterminated106
2024-10-01P3H. Lundbeck A/SNCT04921384 Eptinezumab as Preventive Treatment of Migraine in Adults With MigraineMigrainecompleted981
2024-10-01 est.P3Organ, Tissue, Regeneration, Repair and ReplacementNCT05528328 Post-surgical Scars After the Use of CACIPLIQ20Scarsunknown50
2024-10-01P3BiocadNCT05726630 Clinical Study of Divozilimab in Patients With Systemic SclerodermaSystemic Sclerodermaactive not recruiting152
2024-10-01P3Colgate Palmolive CLNCT06048627 Anti-gingivitis MouthrinseGingivitiscompleted90
2024-10-01P2ServierNCT06081829 A Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 MutationCholangiocarcinoma Non-resectable; Cholangiocarcinoma Metastaticactive not recruiting12
2024-10-02P1/P2AbbVie ABBVNCT03386513 Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCNBlastic Plasmacytoid Dendritic Cell Neoplasm; Myeloproliferative Neoplasmactive not recruiting179
2024-10-02P1/P2EnteromeNCT04187404 A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/ParagangliomaAdrenocortical Carcinoma; Pheochromocytoma; Paragangliomaterminated70
2024-10-02P3Novartis Pharmaceuticals NVSNCT04266301 Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as PMyelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronicterminated530
2024-10-02P2Gilead Sciences GILDNCT04854499 Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell CarcinomaHead and Neck Squamous Cell Carcinomaterminated193
2024-10-02P3Cassava Sciences, Inc.NCT04994483 Simufilam 100 mg for Mild-to-Moderate Alzheimer's DiseaseAlzheimer Diseasecompleted804
2024-10-02 est.P3Novo Nordisk A/S NVONCT05444153 Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and ObesityDiabetes Mellitus, Type 2withdrawn
2024-10-02P2Beckley Psytech LimitedNCT05674929 An Open-Label, Single Dose Study in Patients With Alcohol Use DisorderAlcohol Use Disordercompleted13
2024-10-02P2Vertex Pharmaceuticals Incorporated VERXNCT06176196 Evaluation of Efficacy and Safety of VX-548 for Painful Lumbosacral Radiculopathy (PLSR)Painful Lumbosacral Radiculopathycompleted218
2024-10-02P3Alebund PharmaceuticalsNCT07030595 AP301 Efficacy and Safety in Chinese Dialysis Patients With HyperphosphatemiaESRD (End Stage Renal Disease); Chronic Kidney Disease(CKD); Hyperphosphatemia; Hyperphosphatemia incompleted474
2024-10-03P3CelgeneNCT03464097 A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's DiseaseCrohn Diseaseterminated550
2024-10-03P1/P2Kymab LimitedNCT03829501 A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab)Squamous Cell Carcinoma of Head and Neck; Non-small Cell Lung Cancer; Hepatocellular Carcinoma; Esopterminated222
2024-10-03P3Corestemchemon, Inc.NCT04745299 Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients With ALSAmyotrophic Lateral Sclerosiscompleted123
2024-10-03P3Mannkind Corporation MNKDNCT04974528 Afrezza® INHALE-1 Study in PediatricsDiabetes Mellitus, Type 1; Diabetes Mellitus, Type 2completed319
2024-10-03P3Kashiv BioSciences, LLCNCT05774639 Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic UrticariaChronic Idiopathic Urticariacompleted600
2024-10-04P1/P2CRISPR Therapeutics AG CRSPNCT04035434 A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)B-cell Malignancy; Non-Hodgkin Lymphoma; B-cell Lymphoma; Adult B Cell ALLterminated93
2024-10-04P2Algiax Pharmaceuticals GmbHNCT04429919 AP-325 in Subjects With Peripheral Post-surgical Neuropathic PainPeripheral Post-surgical Neuropathic Paincompleted99
2024-10-04P3Apsen Farmaceutica S.A.NCT04647435 Efficacy and Safety of APSCTC for the Treatment of Postsurgical Pain Due to Third Molar ExtractionPostsurgical Pain; Third Molar Extractioncompleted396
2024-10-04P3AbbVie ABBVNCT05439616 Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-Autism Spectrum Disordercompleted161
2024-10-04P2Shanghai Pharma Biotherapeutics USA Inc.NCT05580588 Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic LiposarcomasLiposarcoma, Dedifferentiatedterminated14
2024-10-04P2GH Research Ireland LimitedNCT05800860 A Trial of GH001 in Patients With Treatment-resistant DepressionTreatment-resistant Depressioncompleted81
2024-10-04P3Laboratorios Silanes S.A. de C.V.NCT06517823 Efficacy and Safety of Etoricoxib/Cyanocobalamin Versus Etoricoxib for Acute Low Back PainAcute Low-back Paincompleted190
2024-10-05P2Ferring PharmaceuticalsNCT05403476 A Trial to Compare Efficacy and Safety of Follitropin Delta Versus Placebo (Inactive Treatment) in the Treatment of Men With Idiopathic Infertility (UnexplainedMale Idiopathic Infertilityterminated4
2024-10-05P3Otsuka Pharmaceutical Co., Ltd.NCT05687071 A Long-term Trial of ETC-1002 in Patients With Hyper-LDL CholesterolemiaHyper-low-density Lipoprotein (LDL) Cholesterolemiacompleted130
2024-10-05P2Haisco Pharmaceutical Group Co., Ltd.NCT06703268 A Study on Switching From Daily DPP-4 Inhibitor to HSK7653 in Type 2 Diabetes PatientsType 2 Diabetescompleted64
2024-10-07P1/P2GlaxoSmithKlineNCT03866187 Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic HepatitHepatitis B, Chronicterminated236
2024-10-07P3AstraZeneca AZNNCT04493853 Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN DeficiencyHormone-Sensitive Prostate Canceractive not recruiting1012
2024-10-07P2AstraZeneca AZNNCT04999969 Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid TumoursLocally Advanced or Metastatic Solid Tumoursactive not recruiting126
2024-10-07 est.P1/P2Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT05435274 Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung CancerAdvanced Non-Small-Cell Lung Cancerunknown380
2024-10-07P1/P2QC Kinetix LLCNCT05742763 Platelet-Rich Plasma and the Effects of NSAIDs on Pain and Functional Scores in Knee OsteoarthritisOsteoarthritis of the Knee; Degenerative Osteoarthritis; Knee Pain Chronicwithdrawn
2024-10-07P1/P2Aelis FarmaNCT05748405 Phase 1/2 Trial of AEF0217 in Participants With Down SyndromeDown Syndromecompleted40
2024-10-07P3Incyte Corporation INCYNCT05755438 A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)Prurigocompleted204
2024-10-07P2Boehringer IngelheimNCT05865886 A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™)Cystic Fibrosis; Bronchiectasiscompleted22
2024-10-07P2Arctic BioscienceNCT06125808 Efficacy and Safety Study of HRO350 in Patients with Mild-to-moderate Psoriasis (the 'HeROPA' Study).Psoriasiscompleted521
2024-10-07 est.P1/P2SUNHO(China)BioPharmaceutical CO., Ltd.NCT06255964 A Study of IAP0971 in Combination With Bacillus Calmette Guerin in High Risk Non-muscular Invasive Bladder CancerBladder Cancernot yet recruiting236
2024-10-08P2Gilead Sciences GILDNCT04958785 Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast CancerTriple-Negative Breast Cancerterminated92
2024-10-08 est.P2American Regent, Inc. AIGNCT04968379 Safety, Tolerability, PK and PD of Intravenous Ferric Carboxymaltose in Infants With Iron Deficiency AnemiaIron Deficiency, Anaemiawithdrawn
2024-10-08P2Spero Therapeutics SPRONCT05496374 A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared With Placebo for the Treatment of Participants With MycobacteNontuberculous Mycobacterial Pulmonary Disease (NTM-PD)completed25
2024-10-08P2Amgen AMGNNCT05669599 Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes MObesity; Overweight; Type 2 Diabetes Mellituscompleted592
2024-10-08P3Braintree LaboratoriesNCT05890001 A Study to Evaluate the Long-Term Safety of BLI5100 in Patients With Gastroesophageal Reflux DiseaseNon-erosive Reflux Disease; Erosive Esophagitiscompleted400
2024-10-09P3Novartis Pharmaceuticals NVSNCT04353492 An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or FingRelapsing Multiple Sclerosiscompleted562
2024-10-09P3Eli Lilly and Company LLYNCT05963022 A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)Type 2 Diabetescompleted206
2024-10-09P3Arcturus Therapeutics, Inc. ARCTNCT06279871 Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in AdultsCOVID-19completed1514
2024-10-10P3Bristol-Myers Squibb BMYNCT04908202 A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to BioPsoriatic Arthritisactive not recruiting670
2024-10-10P3Merck Sharp & Dohme LLC MRKNCT05631093 A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral HIV-1 Infectionactive not recruiting553
2024-10-10P2Eli Lilly and Company LLYNCT05911841 A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic DermatitisAtopic Dermatitisterminated234
2024-10-10P2Omeros Corporation OMERNCT05972967 Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to RavulizumabParoxysmal Nocturnal Hemoglobinuriacompleted12
2024-10-10P1/P2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06434103 Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLCAdvanced Non-small Cell Lung Cancerwithdrawn
2024-10-10P3Applied Biology, Inc.NCT06484881 Clinical Study of Probiotic Treatment for Androgenetic AlopeciaAndrogenetic Alopecia; Female Pattern Baldnesswithdrawn
2024-10-10P2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT06509958 Phase Ⅱ Study of Adductor Canal Block With HR18034 for Postsurgical Pain Management in TKAPostoperative Pain Management in Total Knee Arthroplastyterminated15
2024-10-10P2Aquestive Therapeutics AQSTNCT06527937 Pharmacokinetics Study of DESF in Adults With Oral Allergy SyndromeAllergic Reactioncompleted36
2024-10-11P3ActelionNCT04175600 A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial HypertensionHypertension, Pulmonaryactive not recruiting138
2024-10-11P2Sanofi SNYNCT05421598 Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe AsthmaAsthmacompleted437
2024-10-11P2GemVax & KaelNCT05819658 GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP)Progressive Supranuclear Palsycompleted78
2024-10-11P3Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.NCT06739044 Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 DiabetesType 2 Diabetescompleted494
2024-10-12P2/P3Applied Therapeutics, Inc. AMATNCT05397665 Pharmacodynamic EffIcacy and Clinical Benefit of AT 007 in Patients With Sorbitol Dehydrogenase (SORD) DeficiencyHereditary Neuropathy Caused by SORD Deficiencycompleted56
2024-10-13P2Fujian Shengdi Pharmaceutical Co., Ltd.NCT05881837 A Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Obese Subjects Without DiabetesOverweight or Obesitycompleted249
2024-10-14 est.P2Effector TherapeuticsNCT04622007 Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)Non-small Cell Lung Cancerunknown68
2024-10-14P3Intra-Cellular Therapies, Inc.NCT05061719 An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderMajor Depressive Disordercompleted812
2024-10-14P2Wex Pharmaceuticals Inc. WEXNCT05359133 A Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Trial of Single Cycle Tetrodotoxin in the Treatment of Chemotherapy Induced NeuChemotherapy-induced Neuropathic Pain; Chemotherapy-induced Peripheral Neuropathyterminated35
2024-10-14P2GlaxoSmithKlineNCT05838755 A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic PainPainterminated147
2024-10-14P2Travere Therapeutics, Inc. TVTXNCT05856760 A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgANImmunoglobulin A Nephropathycompleted48
2024-10-15P3AstraZeneca AZNNCT04351555 A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Non-Small Cell Lung Canceractive not recruiting358
2024-10-15P2Principia Biopharma, a Sanofi CompanyNCT04520451 Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease ParticipantsImmunoglobulin G4 Related Diseasecompleted27
2024-10-15 est.P2CellSight Technologies, Inc.NCT04726215 Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung CancerNon Small Cell Lung Cancerunknown50
2024-10-15 est.P2/P3Paradigm Biopharmaceuticals USA (INC)NCT04809376 Treatment Effects of Subcutaneous Injections of Pentosan Polysulfate Sodium vs Placebo in Participants With Knee OA PainOsteoarthritis, Kneeactive not recruiting602
2024-10-15P1/P2Eisai Inc.NCT05091346 A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid TumorsMelanoma; Carcinoma, Hepatocellular; Colorectal Neoplasmscompleted89
2024-10-15P2/P3Sling Therapeutics, Inc.NCT05276063 A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)Thyroid Eye Disease; Graves Orbitopathy; Endocrine System Diseases; Eye Diseases; Thyroid Associatedcompleted90
2024-10-15P2PureTech PTCHFNCT05321420 LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary Fibrosisactive not recruiting240
2024-10-15P1/P2Vir Biotechnology, Inc. VIRNCT05612581 A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B InfectionHepatitis B, Chroniccompleted33
2024-10-15P1/P2IVIEW Therapeutics Inc.NCT06400459 IVW-1001 Phase 1/2 in Subjects With Dry Eye DiseaseDry Eye Diseasecompleted150
2024-10-15P3Novavax NVAXNCT06409663 A Strain Change Study for SARS-CoV-2 rS VaccinesSevere Acute Respiratory Syndrome Coronavirus 2 Infectioncompleted60
2024-10-15 est.P1/P2Frontera TherapeuticsNCT06492863 Gene Therapy(FT-003) for Wet AMDNeovascular Age-related Macular Degenerationrecruiting78
2024-10-15P2Dexa Medica GroupNCT06558006 Safety and Efficacy Predimenol for HeadacheHeadachecompleted60
2024-10-16P3NovoCure Ltd. NVCRNCT03377491 Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-pPancreas Adenocarcinomacompleted571
2024-10-16P2Kinevant Sciences GmbHNCT05314517 A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary SarcoidosisSarcoidosis, Pulmonaryterminated107
2024-10-16P3Amylyx Pharmaceuticals Inc. AMLXNCT05619783 Extension Study Evaluating The Safety And Tolerability of AMX0035Amyotrophic Lateral Sclerosiscompleted352
2024-10-16P2AnaptysBio, Inc. ANABNCT05935085 This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD).Atopic Dermatitis Eczematerminated201
2024-10-16P1/P2Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT06106841 TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)Mantle Cell Lymphomaterminated19
2024-10-16P3Gunkang Pharmaceuticals, IncNCT06317350 Clinical Study to Evaluate the Efficacy and Safety of GNS-212-E in Bowel Preparation for ColonoscopyColonoscopy; Bowel Preparationcompleted318
2024-10-17P3Novartis Pharmaceuticals NVSNCT05630001 Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan.Paroxysmal Nocturnal Hemoglobinuriacompleted52
2024-10-17P3Novartis Pharmaceuticals NVSNCT05722522 Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff TendinopathyRotator Cuff Tendinopathyterminated33
2024-10-17P3Novartis Pharmaceuticals NVSNCT05758415 Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff TendinopathyRotator Cuff Tendinopathyterminated60
2024-10-17P2Staidson (Beijing) Biopharmaceuticals Co., LtdNCT06289166 Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with InhibitorHemophiliacompleted25
2024-10-17P2Grand Theravac Life Sciences (Nanjing) Co., Ltd.NCT07190742 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in Treated PatientChronic Hepatitis B Virusactive not recruiting80
2024-10-18P1/P2CARsgen Therapeutics Co., Ltd.NCT04581473 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell InjectionGastric Adenocarcinoma; Pancreatic Cancer; Gastroesophageal Junction Adenocarcinomaactive not recruiting192
2024-10-18P3Boehringer IngelheimNCT04846881 Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)Schizophreniacompleted611
2024-10-18P3Vertanical GmbHNCT05610813 Comparison of VER-01 to Opioids in Patients With Chronic Non-specific Low Back PainChronic Non-specific Low Back Paincompleted384
2024-10-18P3GlaxoSmithKlineNCT05682326 Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric (ASCEND-P)Anaemiacompleted4
2024-10-18P2Ascendis Pharma Endocrinology Division A/S ASNDNCT05690386 A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner SyndromeTurner Syndromeactive not recruiting48
2024-10-18P2Kissei Pharmaceutical Co., Ltd.NCT05831670 An Early Phase 2 Clinical Study of KSP-0243Colitis, Ulcerativecompleted108
2024-10-18P2Caliway Biopharmaceuticals Co., Ltd.NCT06005441 A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat.Subcutaneous Fatcompleted173
2024-10-18P1/P2Chengdu Baiyu Pharmaceutical Co., Ltd.NCT06524804 A Phase Ib/II Study of BY101298 , an Oral DNA-PK Inhibitor, Combined with Radiotherapy in Patients with Malignant Solid TumorsSolid Tumor, Adultterminated60
2024-10-18P3Shenzhen Salubris Pharmaceuticals Co., Ltd.NCT06720233 Efficacy and Safety Study of SAL-0951 in the Treatment of Renal Anemia in Patients Receiving Peritoneal DialysisAnemiacompleted37
2024-10-20P1/P2Ascentage Pharma Group Inc. AAPGNCT04494503 Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLLChronic Lymphocytic Leukemia; Small Lymphocytic Lymphomarecruiting123
2024-10-20 est.P1/P2Nanjing IASO Biotechnology Co., Ltd.NCT05091541 A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's LymphomaB-cell Non-Hodgkin's Lymphomanot yet recruiting125
2024-10-20 est.P3Xeolas Pharmaceuticals LimitedNCT05602493 A Randomized Control Trial Phase (IIIa) Unicentric, Placebo Controlled, Double-Blinded Efficacy and Safety of Topical Alendronic Acid on Alveolar Bone RemodelinBone Loss, Alveolarunknown60
2024-10-20P2Genentech, Inc.NCT05660850 A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic CoughChronic Refractory Cough (CRC) With Non-atopic Asthma; CRC With Atopic Asthma; Unexplained Chronic Ccompleted49
2024-10-21P2QED Therapeutics, a BridgeBio companyNCT04265651 Study of Infigratinib in Children With AchondroplasiaAchondroplasiacompleted84
2024-10-21P2Otsuka Pharmaceutical Co., Ltd.NCT05615363 A Dose-ranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF])Cardiac Edema (CHF)completed157
2024-10-22P2Bristol-Myers Squibb BMYNCT02060188 A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has SpreadMicrosatellite Unstable Colorectal Cancer; Microsatellite Stable Colorectal Cancer; Mismatch Repair completed385
2024-10-22P3Novartis Pharmaceuticals NVSNCT04632927 Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor TreatmentPsoriatic Arthritiscompleted119
2024-10-22P1/P2Incyte Corporation INCYNCT04809467 A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic LyChronic Lymphocytic Leukemia; Non Hodgkin Lymphomaterminated54
2024-10-22P3SBI ALApharma Canada, Inc.NCT04815083 Fluorescence Imaging of Carcinoma During Breast Conserving SurgeryBreast Neoplasm Female; Breast Cancerterminated57
2024-10-22P2Amgen AMGNNCT04987307 Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative ColitisUlcerative Colitisterminated221
2024-10-22P3Ionis Pharmaceuticals, Inc. IONSNCT05079919 A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe HypertriglyceridemiaSevere Hypertriglyceridemiacompleted617
2024-10-22P3Beijing Continent Pharmaceutical Co, Ltd.NCT05115942 Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial.Liver Fibrosiscompleted248
2024-10-22P3GlaxoSmithKlineNCT06331156 A Study on the Immune Response and Safety of Inactivated Poliovirus Vaccine (IPV) When Co-administered With Human Rotavirus (HRV) Porcine Circovirus (PCV)-Free Gastroenteritiscompleted400
2024-10-22P3Colgate Palmolive CLNCT06607172 Clinical Efficacy of the Combined Effect of Oral Irrigator and Chemicals (0.075% CPC)Dental Plaque; Dental Plaque Induced Gingivitis; Dental Plaque and Gingivitis; Gingivitiscompleted30
2024-10-23P3Hoffmann-La RocheNCT03371017 A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast CancerTriple Negative Breast Neoplasmscompleted595
2024-10-23P2/P3LeonaBio LONANCT04886063 Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's DiseaseAlzheimer Diseaseterminated423
2024-10-23P2Jazz Pharmaceuticals JAZZNCT05642442 A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's DiseaseParkinson Disease; Tremorcompleted169
2024-10-23P1/P2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05834543 Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell CarcinomaAdvanced Esophageal Squamous Cell Carcinomaterminated34
2024-10-23P2Tasly Pharmaceutical Group Co., LtdNCT06259526 A Study of the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe DepressionDepressioncompleted267
2024-10-23P2Glyscend, Inc.NCT06259981 A 16-Week Study to Evaluate the Efficacy, Safety, and Tolerability of GLY-200 in Participants With ObesityObesitycompleted75
2024-10-24P2Iovance Biotherapeutics, Inc. IOVANCT02360579 Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic MelanomaMetastatic Melanomacompleted220
2024-10-24P1/P2Helix BioPharma Corporation HLXCNCT04203641 L-DOS47 Plus Doxorubicin in Advanced Pancreatic CancerPancreas Cancerterminated28
2024-10-24P2Hoffmann-La RocheNCT04980222 A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOLymphomaactive not recruiting46
2024-10-24P1/P2Palleon Pharmaceuticals, Inc.NCT05259696 Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)Oncology; Melanoma; Ovarian Cancer; NSCLC; Non Small Cell Lung Cancer; Colorectal Cancer; Pancreaticcompleted69
2024-10-24P2NeuroBo Pharmaceuticals Inc.NCT06054815 Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASHNON-ALCOHOLIC STEATOHEPATITIScompleted109
2024-10-24P2EyePoint Pharmaceuticals, Inc. EYPTNCT06099184 Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)Diabetic Macular Edemacompleted27
2024-10-25P3Bristol-Myers Squibb BMYNCT02477826 An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum DoubleNon-Small Cell Lung Cancercompleted2747
2024-10-25P1/P2Hope Biosciences LLC HOPENCT04063215 A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury aTraumatic Brain Injurycompleted24
2024-10-25P2Novartis Pharmaceuticals NVSNCT04150029 A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for ChemotherapyAcute Myeloid Leukemiaterminated90
2024-10-25P1/P2Accendatech USA Inc.NCT05053880 A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma MultiformeRecurrent Glioblastoma Multiforme(GBM)active not recruiting48
2024-10-25P2ABLi Therapeutics, Inc.NCT05424276 A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's DiseaseParkinson Diseasecompleted137
2024-10-25P3Merck Sharp & Dohme LLC MRKNCT05630755 A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/EmtHIV-1 Infectionactive not recruiting514
2024-10-25 est.P2Shandong New Time Pharmaceutical Co., LTDNCT05741021 A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Non-small Cell Lung Cancer; NSCLC; PD-1unknown84
2024-10-25P1/P2Aurion BiotechNCT06041256 A Phase 1/2 Study of AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction (ABA-1)Corneal Edema; Corneal Endothelial Dysfunctioncompleted97
2024-10-27P2Novartis Pharmaceuticals NVSNCT06097663 A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart DCoronary Heart Disease; Clonal Hematopoiesis of Indeterminate Potential (CHIP)completed31
2024-10-28P2Zydus Therapeutics Inc.NCT03617263 Saroglitazar Magnesium 4 mg in the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Women With PCOS (EVIDENCES VII)Non-alcoholic Fatty Liver Disease in Women With PCOSterminated60
2024-10-28P2Merck Sharp & Dohme LLC MRKNCT03797326 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G0Advanced Solid Tumors; Triple Negative Breast Cancer; Ovarian Cancer; Gastric Cancer; Colorectal Cancompleted611
2024-10-28P3Eurofarma Laboratorios S.A.NCT04233190 A Multicenter, Randomized, Parallel, Two-Period, Non-Inferiority Study of EurofarmavsAlenia in Asthma and COPD TreatmentAsthma Copdcompleted472
2024-10-28P3Insmed Incorporated INSMNCT04594369 A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis BronchiectasisNon-Cystic Fibrosis Bronchiectasiscompleted1767
2024-10-28P2AstraZeneca AZNNCT04605549 A Study of CIN-107 in Adults With Primary AldosteronismPrimary Aldosteronism; Hyperaldosteronismcompleted15
2024-10-28P2/P3PT Bio FarmaNCT04741828 Persistence and Long-Term Protection of Vi Antibodies Induced by Vi-DT Conjugate Vaccines in IndonesianVaccinecompleted188
2024-10-28P3AstraZeneca AZNNCT04765059 A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)Non-small Cell Lung Canceractive not recruiting98
2024-10-28P3Boehringer IngelheimNCT04860830 CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With SchizophreniaSchizophreniacompleted609
2024-10-28P3Janssen Research & Development, LLCNCT04936308 Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha AgentArthritis, Psoriaticcompleted453
2024-10-28P3GlaxoSmithKlineNCT04950127 Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)Prurituscompleted238
2024-10-28P2Binhui Biopharmaceutical Co., Ltd.NCT05248789 OH2 Oncolytic Viral Therapy in Advanced Bladder CancerAdvanced Bladder Carcinomaterminated4
2024-10-28P2AbbVie ABBVNCT05513703 A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small CelNon Small Cell Lung Cancerterminated9
2024-10-28P3Novo Nordisk A/S NVONCT05649137 A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose WeightObesity; Diabetes Mellitus, Type 2completed512
2024-10-28P2Incannex Healthcare Ltd IXHLNCT05942911 Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid ArthritisRheumatoid Arthritisterminated20
2024-10-28P1/P2Clinuvel Europe Limited CUVLNCT06388642 Pharmacokinetics of Afamelanotide in Erythropoietic Protoporphyria PatientsErythropoietic Protoporphyriacompleted28
2024-10-28P1/P2Norroy Bioscience Co., LTDNCT06389695 Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM032 in PatientsProstate Cancercompleted20
2024-10-29P3Baxalta now part of ShireNCT02615691 A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia AHemophilia Acompleted120
2024-10-29P1/P2Takeda TAKNCT04381650 A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid TumorsAdvanced or Metastatic Solid Tumorscompleted161
2024-10-29P3Merck Sharp & Dohme LLC MRKNCT04662710 Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal AdenoAdvanced/Metastatic Gastroesophageal Adenocarcinomacompleted895
2024-10-29P1/P2Inozyme PharmaNCT04686175 Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ENPP1 DeficiencyEctonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency; Autosomal Recessive Hypophosphatemic Rcompleted13
2024-10-29P3Zealand Pharma ZEAL.CONCT05378672 A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1DHypoglycemia; Type 1 Diabetescompleted8
2024-10-29P2TFF Pharmaceuticals, Inc.NCT05501574 An Open Label Trial Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetic Profile of Tacrolimus Inhalation Powder in Adult Lung Transplant RecipientLung Transplant Rejectionterminated14
2024-10-29P3CSL BehringNCT05568888 Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study )Traumatic Injuryterminated1366
2024-10-29P3RemeGen Co., Ltd.NCT05673993 A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's SyndromePrimary Sjogren's Syndromecompleted381
2024-10-29P1/P2Cellcolabs Clinical SPV LimitedNCT06084988 A Study to Evaluate the Safety of Human Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Product StromaForte for the Treatment of Knee OsteoarthritisOsteo Arthritis Kneecompleted12
2024-10-29P2Fujian Shengdi Pharmaceutical Co., Ltd.NCT06475846 A Trial of HRS5580 in Prevention of Postoperative Nausea and Vomiting of AdultsPreventing of Postoperative Nausea and Vomiting in Adultscompleted235
2024-10-30P2Incyte Corporation INCYNCT03011372 A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)MPN (Myeloproliferative Neoplasms)completed47
2024-10-30P3Laboratorios Sophia S.A de C.V.NCT03193333 PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM)Primary Open-angle Glaucomaterminated51
2024-10-30P3Serum Institute of India Pvt. Ltd.NCT04351685 Evaluation of Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Tb Infection in InfantsMycobacterium Tuberculosis Infectioncompleted6940
2024-10-30P3Eurofarma Laboratorios S.A.NCT04384367 Efficacy and Safety of Rizatriptan-Naproxen (10/550 mg) in the Acute Treatment of MigraineMigrainecompleted2068
2024-10-30P2Merck Sharp & Dohme LLC MRKNCT05027074 Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-20End-Stage Renal Disease; End-Stage Kidney Disease; Kidney Failure, Chroniccompleted506
2024-10-30P2Archivel Farma S.L.NCT05455112 Safety and Efficacy of RUTI® With the Standard of Treatment for TuberculosisTuberculosis, Pulmonarycompleted41
2024-10-30P3NobelpharmaNCT05495425 Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSCTuberous Sclerosis Complexcompleted43
2024-10-30 est.P2Shanghai Henlius BiotechNCT05528406 A Phase II Clinical Trial to Evaluate HLX208 in Advanced Solid Tumor Patients With BRAF V600 MutationSolid Tumorunknown30
2024-10-30P3Novo Nordisk A/S NVONCT05567796 A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose WeightObesityactive not recruiting3400
2024-10-30P3Novo Nordisk A/S NVONCT05646706 A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)Obesitycompleted1407
2024-10-30 est.P2Genrix (Shanghai) Biopharmaceutical Co., Ltd.NCT05873803 The Study of GR1802 in Patients with Chronic Rhinosinusitis with Nasal PolypsChronic Rhinosinusitis with Nasal Polypsunknown70
2024-10-30 est.P2Shanghai Ming Ju Biotechnology Co., Ltd.NCT06149169 CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell LymphomaLymphoma, Non-Hodgkin; Diffuse Large B Cell Lymphomaunknown10
2024-10-30 est.P2Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.NCT06500299 Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese AdultsOverweight and Obesityunknown180
2024-10-31P3CelgeneNCT03467958 An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's DiseaseCrohn Diseaseterminated854
2024-10-31P3Tesaro, Inc.NCT03602859 A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IOvarian Neoplasms; Ovarian, Fallopian Tube and Primary Peritoneal Carcinomaactive not recruiting1400
2024-10-31P3Eyenovia Inc.NCT03942419 Microdosed Atropine 0.1% and 0.01% Ophthalmic Solutions for Reduction of Pediatric Myopia ProgressionMyopiaterminated438
2024-10-31P2Fulcrum Therapeutics FULCNCT04004000 Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1 With ExtensionFacioscapulohumeral Muscular Dystrophy 1terminated14
2024-10-31P2Spruce Biosciences SPRBNCT04544410 A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAHCongenital Adrenal Hyperplasiaterminated100
2024-10-31P2Regeneron Pharmaceuticals REGNNCT04916002 A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic CancerMerkel Cell Carcinoma; Cutaneous Squamous Cell Carcinoma; Basal Cell Carcinoma; Triple Negative Breaterminated77
2024-10-31P1/P2ESSA PharmaceuticalsNCT05075577 EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPCProstate Cancerterminated77
2024-10-31 est.P3Reistone Biopharma Company LimitedNCT05181137 A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative ColitisUlcerative Colitisunknown368
2024-10-31P2Chipscreen Biosciences, Ltd.NCT05336721 A Phase II Study of Chiauranib in Combine With Capecitabine in TNBCTriple-negative Breast Cancerterminated9
2024-10-31P1/P2Chimagen Biosciences, LtdNCT05348889 First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic MalignanciesNon-Hodgkin's Lymphoma (disorder); Acute Lymphoid Leukemia, Disease (disorder)terminated7
2024-10-31P2XBiotech, Inc. XBITNCT05363891 Natrunix or Placebo in Combination With Methotrexate in Rheumatoid ArthritisRheumatoid Arthritiscompleted243
2024-10-31 est.P1/P2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT05445154 SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)Newly Diagnosed Acute Myeloid Leukemia (AML)recruiting58
2024-10-31 est.P1/P2Shanghai Gopherwood Biotech Co., Ltd.NCT05505877 Phase I/IIa Study of BR790 in Combination With Tislelizumab in Adult Subjects With Advanced Solid TumorsAdvanced Solid Tumorunknown160
2024-10-31P2Arcturus Therapeutics, Inc. ARCTNCT05526066 Study for Adolescents and Adults With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerability of ARCT-810Ornithine Transcarbamylase Deficiency; OTC Deficiency; OTCDterminated8
2024-10-31P2Amgen AMGNNCT05672199 Long-term Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative ColitisUlcerative Colitisterminated25
2024-10-31P2Vergent Bioscience, Inc.NCT06145048 Phase 2B Safety and Efficacy Study of VGT-309 in Subjects With Cancer in the Lung.Lung Cancer; Lung Metastasescompleted89
2024-10-31P3Lahore Medical Research Center, LLPNCT06317064 Diagnostic and Therapeutic Potential of Substance P/ NK1R Receptor in Primary DysmenorrheaPrimary Dysmenorrheacompleted40
2024-10-31 est.P2CSPC Ouyi Pharmaceutical Co., Ltd.NCT06354114 A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011Advanced Breast Cancernot yet recruiting80

← 2024-09 | 2024-11 →

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.